Tag: Biotech

Posted on

Pancreatic Cancer Cell Death Triggered by Caspase‑8 Blockade in Preclinical Models

Pancreatic cancer remains one of the most lethal malignancies, notorious for its late detection, rapid progression, and stubborn resistance to many therapeutic strategies clinicians have tried. Despite decades of effort, standard treatments have delivered only incremental gains, and the disease is projected to become the second leading cause of cancer‑related death within this decade. Now, researchers at the University of Cologne’s Center for Molecular Medicine Cologne (CMMC) have uncovered a surprising vulnerability in KRAS‑mutant pancreatic tumors—one that primes them for a potent form of programmed cell death.

In a study published in Nature Communications titled “Oncogenic KRAS-driven type I interferon signaling primes pancreatic cancer for necroptosis,” the team reported that oncogenic KRAS, the defining driver mutation in roughly 90% of pancreatic ductal adenocarcinomas (PDAC), activates a type I interferon signaling program that inadvertently primes tumor cells to necroptosis, an inflammatory form of regulated cell death. However, “KRAS‑mutated tumors have a previously unknown Achilles heel,” said senior author Silvia von Karstedt, PhD. “By switching off the tumor cells’ defense mechanisms, we can significantly kill these tumors.”

The defense mechanism in question is caspase‑8, a protein long known for its role in apoptosis but increasingly recognized as a gatekeeper that prevents necroptosis. The Cologne team found that KRAS‑driven interferon signaling induces high expression of necroptosis‑related interferon‑stimulated genes—including MLKL—creating a state in which tumor cells become heavily dependent on caspase‑8 for survival.

Using genetically engineered mouse models, the researchers showed that deleting caspase‑8 specifically in KRAS‑driven pancreatic lesions triggered widespread necroptotic cell death and eliminated most precursor lesions. “Cancer cell-specific deletion of caspase‑8 is sufficient to trigger necroptotic cell death, eliminating most pancreatic precursor lesions,” the authors reported in their paper.

Furthermore, in aggressive PDAC mouse models and human patient‑derived tumor organoids, pharmacologic caspase inhibition significantly reduced tumor burden.

First author Sofya Tishina, PhD, emphasizes the translational potential: “The findings provide strong evidence that certain forms of pancreatic cancer could be specifically targeted for treatment based on their dependence on caspase‑8. In the long term, this could help develop new therapies for patients who currently have very limited treatment options.”

Beyond pancreatic cancer, the study’s pan‑cancer transcriptomic analysis revealed that tumors with high Ras pathway activity and strong interferon signatures also exhibit elevated necroptosis gene expression, hinting at broader applicability. As the authors concluded in their paper, their work “reveals a KRAS-induced IFN program that sensitizes tumor cells to necroptosis, highlighting a therapeutic vulnerability in PDAC with broader relevance across IFN-activated cancers.”

The post Pancreatic Cancer Cell Death Triggered by Caspase‑8 Blockade in Preclinical Models appeared first on GEN – Genetic Engineering and Biotechnology News.

Posted on

Six Takeaways from the Danaher Bioprocessing Summit

The Danaher Bioprocessing Summit, “The Next Era of Bioprocessing: From Promise to Patient Impact,” took place in London earlier this month. The event brought together officials from Danaher companies (Cytiva, Pall, Beckman Coulter Life Sciences, IDBS, and Leica Microsystems), along with biopharma manufacturers and researchers to discuss how the industry can accelerate the transition from scientific breakthroughs to commercial therapies.

Key themes included:

  • AI-driven bioprocess development and manufacturing
  • Intensified and continuous bioprocessing
  • Digitalization and connected data ecosystems
  • Improving productivity and reducing cost of goods
  • Cell and gene therapy manufacturing challenges
  • Scaling production of high-demand biologics, including GLP-1 therapies
  • Advanced analytics and process control
  • Sustainability in biomanufacturing

The conference emphasized that future competitive advantage in biomanufacturing will come less from building additional capacity and more from increasing productivity, speed, and process intelligence across the development-to-manufacturing workflow.

Based on the formal presentations, roundtable discussion groups, and conversations among speakers, panelists, and attendees, six key takeaway ideas emerged.

The old manufacturing playbook no longer fits

Biomanufacturing was built for large batches of standardized therapies. The next generation of medicines—cell and gene therapies, targeted and complex biologics, N-of-1 treatments—doesn’t fit that mold. As molecular diversity increases, the field is shifting toward smaller, parallel and distributed systems that can flex to meet the complexity of individualized medicine. This means faster decision-making, new investment models, and process designs that are data-driven and purpose-built from the start rather than adapted from previous playbooks.

Manufacturing can no longer be treated as a downstream problem. It has to be part of the scientific conversation from day one.

Automation and AI are making personalized scale possible

For years, the promise of personalized medicine ran into a hard wall: you can’t manufacture one patient’s therapy the same way you manufacture a million doses of a traditional drug. Integrating automation, AI and high-throughput experimentation is changing that equation.

These tools are enabling a shift from large-batch production to small-batch and even patient-specific manufacturing while improving efficiency, regulatory consistency, and access to advanced therapies. AI and digital tools are also compressing process development timelines, making it possible to design more tailored, adaptive manufacturing approaches without sacrificing rigor.

Prediction is becoming a competitive advantage

The organizations gaining ground are not merely reacting to problems faster but actually anticipating them. Digital twins powered by integrated data are helping teams model outcomes before committing resources, accelerating timelines and reducing risk. And real-time, molecular and submolecular-level data—shared across interoperable systems—are enabling more precise, proactive decision-making at every stage of development and manufacturing. Investing in this area with critical infrastructure is essential.

Breakthroughs require collaboration across the whole ecosystem

It turned out that the most consistent theme across both days of the Summit was this: no single organization can accomplish what’s needed alone. Partnerships across academia, industry, and regulators are accelerating how all kinds of therapies, especially gene therapies, move from discovery to approved treatment. Earlier alignment between developers, manufacturers, and regulators is reducing friction and compressing timelines.

A central theme surfaced throughout the conference: the science is not the problem. The bioindustry already possesses powerful technologies and therapeutic capabilities. Future success depends on rapidly implementing them through manufacturing, regulatory alignment, supplier collaboration, and partnerships. Organizations that execute most effectively will shape the next decade of medicine. [Danaher]
A central theme surfaced throughout the conference: the science is not the problem. The bioindustry already possesses powerful technologies and therapeutic capabilities. Future success depends on rapidly implementing them through manufacturing, regulatory alignment, supplier collaboration, and partnerships. Organizations that execute most effectively will shape the next decade of medicine. [Danaher]

What makes these partnerships work is not goodwill alone but transparency, shared incentives, and data-driven collaboration that keeps everyone oriented around the same outcomes. The organizations making the most progress are those treating collaboration as a core capability.

 

Regulatory models are evolving with the science, and sustainability is now a procurement requirement, not a values statement 

 

Most of the frameworks that currently govern drug development were built for an earlier era of medicine. As therapies grow more complex and more personalized, those frameworks must change. Early engagement and risk-based approaches are helping bring complex therapies to patients faster without compromising scientific rigor. For rare diseases, which collectively affect an estimated 300 million people worldwide, tailored regulatory pathways are becoming essential.

Summit speakers agreed that regulators are not the obstacle they’re sometimes assumed to be. They want to move faster too, and building the right collaborative infrastructure makes that possible.

Environmental and social criteria are moving from corporate commitments into day-to-day supplier decisions. Organizations are integrating sustainability standards into procurement frameworks, requiring verified supplier commitments and shared performance targets as part of doing business.

Far from being separate from operational strategy, this is part of building supply chains resilient enough to support long-term innovation at scale. Progress toward net-zero goals, Summit participants agreed, accelerates when sustainability is wired into commercial relationships rather than managed alongside them.

Across two days and numerous conversations, one key point kept surfacing: the science is not the problem. The biopharma industry has the tools, the knowledge, and the therapeutic advances to transform how medicine is made and delivered. What it lacks is the collective will to operationalize them at speed. The next phase of progress will be won in manufacturing facilities, regulatory negotiations, supplier contracts, and partnerships that connect all of them.

The final conclusion: organizations that close the gap first will define what the next decade of medicine looks like.

To watch recorded keynote presentations, panel discussions, and fireside chats from the Danaher Summit on Bioprocessing, click here.

The post Six Takeaways from the Danaher Bioprocessing Summit appeared first on GEN – Genetic Engineering and Biotechnology News.

Posted on

STAT+: ARCH-launched Neumora stops depression program

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Let’s get straight to the news today.

The need-to-know this morning

  • Moderna said Ester Banque joined the company as chief commercial officer. She was formerly president of U.S. operations for Zoetis. Moderna President Stephen Hoge has also been given an expanded role overseeing several of the company’s drug development programs.

New AI model aims to improve trial enrollment

The biotech Verge Labs today released a new AI model that it says will help determine which patients will respond to treatment better, leading to fewer people dropping out while also increasing the statistical power of a trial.

Continue to STAT+ to read the full story…

Posted on

Scramblase Dynamics Uncovered by Single-Vesicle Fluorescence Microscopy

A new single-protein analysis technique gives researchers newfound ability to study scramblases, physiologically important proteins that translocate phospholipids bidirectionally across cell membranes.  

In the study published in Nature Structural & Molecular Biology titled, “A single-vesicle fluorescence microscopy platform to quantify phospholipid scrambling,” researchers from Weill Cornell Medicine and Ruhr University Bochum have developed a fluorescence imaging-based technique to measure the activity rates of individual scramblase proteins. 

“I’m excited about this new platform as it is versatile and provides unprecedented information on exactly how fast a single scramblase works,” said Anant Menon, PhD, professor of biochemistry and biophysics at Weill Cornell Medicine and co-corresponding author of the study.

Scramblases are key drug targets with roles in the assembly of cell membranes, modification of proteins with sugars, cell survival, muscle development and molecular trafficking. Yet, strategies for understanding scramblase dynamics have been limited.

Traditionally, researchers purify scramblase proteins for further study using vesicles to record average scramblase activity. However, this bulk approach is unable to measure the transport rate of individual scramblases and capture how scramblase variability impact biological processes.

The authors used fluorescently-tagged scramblases to achieve high resolution and evaluated a scramblase protein, known as VDAC1, best known as a membrane channel protein within mitochondria. Two copies of VDAC must align to provide a pathway for lipid movement. These dimers have a wide range of scrambling rates, from fewer than 100 to more than 1,000 lipids per second.

“These findings indicate that only certain dimer conformations are capable of rapid scrambling, directly validating predictions from computer simulations,” Menon said.

The team demonstrated the versatility of their approach by applying the platform to measure lipid-scrambling by opsin, a cell-membrane receptor and scramblase that is involved in light-detection in the eye. Results showed that individual opsin proteins scramble lipids faster than VDAC dimers, achieving rates in excess of 10,000 lipids per second.

The new platform can study how drug molecules impact scramblase function. Additionally, the authors aim to combine their functional studies of scramblases with high-resolution imaging to understand how scramblase shape relates to activity rates. The team also plans to use the technique to study other lipid-moving proteins called flippases and floppases.

The post Scramblase Dynamics Uncovered by Single-Vesicle Fluorescence Microscopy appeared first on GEN – Genetic Engineering and Biotechnology News.